ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO842

Effects of Blood Pressure Variability on Mortality in Chronic Hemodialysis Patients: OCTOPUS Study

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular


  • Adachi, Takayuki, Tomishiro Central Hospital, Tomigusuku city, Japan
  • Kohagura, Kentaro, University of the Ryukyus, Nishihara-cho, OKINAWA, Japan
  • Arima, Hisatomi, Fukuoka Uniuversity, Fukuoka, Japan
  • Iseki, Kunitoshi, Tomishiro Central Hospital, Tomigusuku city, Japan

We examined the relationship between blood pressure variability and survival among chronic HD patients.


We previously reported the results of the multi-center prospective, open trial of the Olmesartan Clinical Trial in Okinawa Patients Under Okinawa Dialysis Study (OCTOPUS). In a multicenter, prospective, randomized, open label, blinded-endpoint trial, 469 patients with chronic HD and elevated BP (140–199/90–99 mmHg) were assigned to receive the angiotensin receptor blockade (ARB) olmesartan (at a dose of 10–40 mg daily; n = 235) or another treatment that does not include angiotensin receptor blockers and angiotensin-converting enzyme (ACE) inhibitors (n = 234).
For this study, we examined of 435 patients after excluding those who died within 1 year after registration (N=28) and lack of blood pressure data for more than 2 time (N=6). We adopted the coefficient of variation (CV), which was obtained using 6 pre-HD blood pressure within the first year after registration, as a marker of blood pressure variability. Cox proportional hazard analysis was used to examine the relationship between blood pressure variability and mortality after the 1-year visit with adjustment for age, sex, smoking, DM, HD vintage, and use of angiotensin receptor blockade.


During the mean follow-up of 2.5 years after the 1-year visit, we observed 58 deaths. We used five quintile groups of CV pre-HD systolic blood pressure (Q1 to Q5). The mortality rate was 9.2% (Q1), 12.8% (Q2), 9.1% (Q3), 16.1% (Q4), and 19.5% (Q5), respectively. The adjusted hazard ratio (95% confidence interval) was 1.83 (0.73-4.63) in Q1, 1.83 (0.73-4.63) in Q2, 1.84 (0.77-4.40) in Q4, and 2.42 (1.04-5.62) in Q5 when the Q3 was taken as reference.


Mortality rate was higher among patients with higher pre-HD variability of blood pressure.